Developer docs
API playgroundTry for free, no card

Search company profiles

Lysando

Full company profile

uuid02lphf2

Namestring
Lysando
Legal namestring
LYSANDO AG
Websiteurl
lysando.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Lysando AG is a privately held biotech company headquartered in Triesenberg, Liechtenstein, that develops and commercializes Artilysin® technology — a class of precision-designed antimicrobial molecules that target and eliminate harmful bacteria while preserving beneficial microbiome communities. The company's core technology addresses the global antibiotic resistance crisis through a mechanism that avoids triggering resistance, rebalances biofilms rather than destroying them, and is effective against metabolically inactive persistent bacteria. Lysando applies AI-driven protein design, supported by a proprietary database of over 4,500 constructs and modules, to accelerate the development of new Artilysin® variants. The intellectual property portfolio comprises hundreds of national patents protecting the Artilysin® platform.

The company's product portfolio spans multiple therapeutic areas: wound care solutions for chronic wounds and infections, dermatology products for acne and eczema, Medolysin® as a specialized variant for medical and veterinary applications (including mastitis in dairy cows through the Amicogen partnership), and general microbiome health applications covering pyoderma, UTIs, and related conditions. The primary go-to-market motion is enterprise field sales and direct B2B engagement with pharmaceutical companies, healthcare providers, and research institutions, utilizing contact forms and downloadable brochures rather than standard product distribution channels. Revenue derives from product sales and technology licensing/royalties, though pricing is not publicly disclosed.

Lysando has established strategic partnerships with Amicogen Inc. (a South Korean enzyme specialist with mutual cross-ownership since 2021) and AiCuris Anti-Infective Curies GmbH (collaborating on diabetic foot infections), indicating a co-development and licensing-driven business model. The company has built out its leadership team with specialized hires including a CSO (Yong Chul Shin, Ph.D.), CFO, and Director of Strategy & Business Development, supplemented by four advisory board appointments in 2024. In July 2024, Lysando entered the Ukrainian market through a humanitarian collaboration with Bamberg UA, donating Medolysin® to address antibiotic resistance in Ukrainian hospitals.

Short descriptiontext

Lysando AG is a Liechtenstein-based biotech company developing Artilysin® molecules — precision-designed antimicrobial proteins that target harmful bacteria while preserving microbiome balance. It serves pharmaceutical partners and healthcare providers across wound care, dermatology, and animal health applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTriesenberg, Liechtenstein
HQ citystring
Triesenberg
HQ countrystring
Liechtenstein
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial protein therapeutics, microbiome-friendly treatments, antibiotic resistance solutions, AI-driven protein design, precision antimicrobials
Industry4 codes
PRIMARYHLAMAEAE
Antimicrobials & Anti-infectives
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAHALAC
Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAMAEAH
Dermatology & Allergy Drugs
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Antimicrobial Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Product Sales / Licensing
TypeLicensing Royalties
Description

Lysando develops and commercializes Artilysin-based products for healthcare applications including wound care, dermatology (acne, eczema), and microbiome health. Revenue likely derives from product sales and technology licensing to pharmaceutical and healthcare companies.

lysando.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Artilysin®
Description

A groundbreaking new class of precision-designed molecules that reestablish microbiome harmony and address the root cause of bacterial infections. Artilysins are developed using AI-driven protein design and target harmful bacteria while preserving beneficial microbiome populations.

lysando.com
+1 more record
Core offering1 text field

Lysando develops and commercializes Artilysin® technology, a class of precision-designed antimicrobial protein molecules that selectively eliminate harmful bacteria while preserving beneficial microbiome communities. The company applies AI-driven protein design, supported by a proprietary database of more than 4,500 constructs, to develop therapeutic products for wound care, dermatology (acne, eczema), and animal health applications such as mastitis in dairy cattle. Revenue derives from product sales of Artilysin-based therapeutics and licensing of the underlying technology to pharmaceutical and healthcare partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • No resistance to Artilysins observed despite rigorous testing
Product overview1 text field

Lysando AG is a biotech company that has developed Artilysin® technology as its core platform - a groundbreaking class of precision-designed molecules for microbiome-targeted treatments. The company offers products targeting wound care and dermatology (acne, eczema), with Medolysin® serving as a specialized variant for medical and veterinary applications. Lysando employs AI-driven protein design with a proprietary database of over 4,500 constructs to enable rapid development of new therapeutic candidates. The portfolio centers on microbiome modulation rather than indiscriminate bacterial elimination, positioning Artilysin® as an alternative to conventional antibiotics.

Product and service1 record
1Artilysin®
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-07-01
Description

Innovation meets compassion collaboration where Lysando and Bamberg UA are working together to tackle antibiotic resistance in Ukrainian hospitals with Medolysin donation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-08
Description

Novel approach for the treatment of mastitis in dairy cows, providing an antibiotic-free alternative for livestock health management.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-18
Description

Strategic partnership including general development agreement for novel approaches in microbiome modulation. The partnership includes mutual ownership participations in each other's companies, indicating deep strategic alignment. Collaboration includes treatment of mastitis in dairy cows and potential broader applications in animal and human health.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AiCuris announced expansion of collaboration with Lysando focusing on diabetic foot infections, leveraging Artilysin technology for difficult-to-treat bacterial infections.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AiCuris is a specialty anti-infective company with a broader anti-infective pipeline. As Lysando's announced collaboration partner for diabetic foot infections, it operates in the same anti-infective space but with a wider portfolio beyond microbiome-targeted approaches.

TypeDirect peer
Description

Locus Biosciences develops engineered bacteriophage-based antimicrobials targeting antibiotic-resistant bacteria. Its precision antimicrobial approach for treating resistant infections makes it a direct peer to Lysando's Artilysin technology.

3Phagelux
TypeDirect peer
Description

Phagelux develops phage-based products for bacterial infection control across human health, animal health, and food safety. Its multi-species antimicrobial platform and animal health focus directly parallel Lysando's positioning with Amicogen.

TypeBroad incumbent
Description

Iterum Therapeutics develops antibiotics targeting multi-drug resistant infections. While it operates in the same anti-infective space with conventional small-molecule antibiotics, it represents the established incumbent approach that Artilysins aim to displace.

TypeDirect peer
Description

ContraFect develops lysin-based therapeutics targeting serious bacterial infections, including drug-resistant pathogens. Its lysin modality is mechanistically similar to Artilysins, making it a direct peer in the novel antimicrobial protein space.

TypeDirect peer
Description

Kane Biotech develops biofilm-disrupting antimicrobial wound care products. Its focus on biofilm management in wound applications directly overlaps with Lysando's wound care use case, even though the underlying modality differs.

TypeDirect peer
Description

Eligo Bioscience develops precision antimicrobials using engineered phage-derived payloads to selectively eliminate specific bacteria. Its microbiome-preserving approach for targeted bacterial elimination directly parallels Lysando's Artilysin strategy.

TypeEmerging player
Description

MatriSys Bioscience develops live biotherapeutic products targeting skin microbiome for dermatological conditions. Its microbiome-focused approach to skin diseases provides a partial overlap with Lysando's dermatology indications.

TypeEmerging player
Description

Siolta Therapeutics develops microbiome-based therapeutics for inflammatory diseases including atopic dermatitis. Its focus on microbiome modulation for skin conditions overlaps with Lysando's dermatology use cases (acne, eczema).

TypeDirect peer
Description

Micreos develops endolysin-based antimicrobial products (e.g., Staphefekt) that selectively target pathogenic bacteria while preserving beneficial microbiome. Its technology is the closest analog to Lysando's Artilysin platform, making it a direct peer in the precision antimicrobial space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lysando

Antimicrobial Therapeuticslysando.com

Lysando AG is a Liechtenstein-based biotech company developing Artilysin® molecules — precision-designed antimicrobial proteins that target harmful bacteria while preserving microbiome balance. It serves pharmaceutical partners and healthcare providers across wound care, dermatology, and animal health applications.

What Lysando does

Lysando AG is a privately held biotech company headquartered in Triesenberg, Liechtenstein, that develops and commercializes Artilysin® technology — a class of precision-designed antimicrobial molecules that target and eliminate harmful bacteria while preserving beneficial microbiome communities. The company's core technology addresses the global antibiotic resistance crisis through a mechanism that avoids triggering resistance, rebalances biofilms rather than destroying them, and is effective against metabolically inactive persistent bacteria. Lysando applies AI-driven protein design, supported by a proprietary database of over 4,500 constructs and modules, to accelerate the development of new Artilysin® variants. The intellectual property portfolio comprises hundreds of national patents protecting the Artilysin® platform.

The company's product portfolio spans multiple therapeutic areas: wound care solutions for chronic wounds and infections, dermatology products for acne and eczema, Medolysin® as a specialized variant for medical and veterinary applications (including mastitis in dairy cows through the Amicogen partnership), and general microbiome health applications covering pyoderma, UTIs, and related conditions. The primary go-to-market motion is enterprise field sales and direct B2B engagement with pharmaceutical companies, healthcare providers, and research institutions, utilizing contact forms and downloadable brochures rather than standard product distribution channels. Revenue derives from product sales and technology licensing/royalties, though pricing is not publicly disclosed.

Lysando has established strategic partnerships with Amicogen Inc. (a South Korean enzyme specialist with mutual cross-ownership since 2021) and AiCuris Anti-Infective Curies GmbH (collaborating on diabetic foot infections), indicating a co-development and licensing-driven business model. The company has built out its leadership team with specialized hires including a CSO (Yong Chul Shin, Ph.D.), CFO, and Director of Strategy & Business Development, supplemented by four advisory board appointments in 2024. In July 2024, Lysando entered the Ukrainian market through a humanitarian collaboration with Bamberg UA, donating Medolysin® to address antibiotic resistance in Ukrainian hospitals.

Lysando firmographics

Firmographics
Name
Lysando
Legal name
LYSANDO AG
Website
https://lysando.com
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Lysando AG is a Liechtenstein-based biotech company developing Artilysin® molecules — precision-designed antimicrobial proteins that target harmful bacteria while preserving microbiome balance. It serves pharmaceutical partners and healthcare providers across wound care, dermatology, and animal health applications.
Ownership category
akta.pro rank

Lysando industry classification

Industry
Product category
Antimicrobial Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAMAEAE
Antimicrobials & Anti-infectives
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAHALAC
Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAMAEAH
Dermatology & Allergy Drugs
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAEAB
Livestock & Production Animal Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

Keywords

  • Antimicrobial protein therapeutics
  • Microbiome-friendly treatments
  • Antibiotic resistance solutions
  • AI-driven protein design
  • Precision antimicrobials

Where Lysando is headquartered

Location

Headquarters

HQ city
Triesenberg
HQ country
Liechtenstein
HQ region
Europe

Offices1 record

Markets served

Lysando business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales / Licensing: Lysando develops and commercializes Artilysin-based products for healthcare applications including wound care, dermatology (acne, eczema), and microbiome health. Revenue likely derives from product sales and technology licensing to pharmaceutical and healthcare companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Lysando product offering

Product offering

Core offering

Lysando develops and commercializes Artilysin® technology, a class of precision-designed antimicrobial protein molecules that selectively eliminate harmful bacteria while preserving beneficial microbiome communities. The company applies AI-driven protein design, supported by a proprietary database of more than 4,500 constructs, to develop therapeutic products for wound care, dermatology (acne, eczema), and animal health applications such as mastitis in dairy cattle. Revenue derives from product sales of Artilysin-based therapeutics and licensing of the underlying technology to pharmaceutical and healthcare partners.

Product overview

Lysando AG is a biotech company that has developed Artilysin® technology as its core platform - a groundbreaking class of precision-designed molecules for microbiome-targeted treatments. The company offers products targeting wound care and dermatology (acne, eczema), with Medolysin® serving as a specialized variant for medical and veterinary applications. Lysando employs AI-driven protein design with a proprietary database of over 4,500 constructs to enable rapid development of new therapeutic candidates. The portfolio centers on microbiome modulation rather than indiscriminate bacterial elimination, positioning Artilysin® as an alternative to conventional antibiotics.

Differentiator

Problem solved

Functional benefit

Brands

  • Artilysin®: A groundbreaking new class of precision-designed molecules that reestablish microbiome harmony and address the root cause of bacterial infections. Artilysins are developed using AI-driven protein design and target harmful bacteria while preserving beneficial microbiome populations.
  • Medolysin®

Products and services

  • Artilysin®

Quantifiable outcome

  • No resistance to Artilysins observed despite rigorous testing

Companies that use Lysando

Customer profile

Segments5 records

Ideal customer profiles3 records

Lysando technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Lysando partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Bamberg UA (Ukrainian Association)minorGTM or Marketing Partner · 1 July 2024Innovation meets compassion collaboration where Lysando and Bamberg UA are working together to tackle antibiotic resistance in Ukrainian hospitals with Medolysin donation.
  • Amicogen Inc.coreStrategic or Co-development Partner · 8 May 2023Novel approach for the treatment of mastitis in dairy cows, providing an antibiotic-free alternative for livestock health management.
  • Amicogen Inc.coreStrategic or Co-development Partner · 18 October 2022Strategic partnership including general development agreement for novel approaches in microbiome modulation. The partnership includes mutual ownership participations in each other's companies, indicating deep strategic alignment. Collaboration includes treatment of mastitis in dairy cows and potential broader applications in animal and human health.
  • AiCuris Anti-Infective Curies GmbHcoreStrategic or Co-development PartnerAiCuris announced expansion of collaboration with Lysando focusing on diabetic foot infections, leveraging Artilysin technology for difficult-to-treat bacterial infections.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Lysando competitors and assessment

Company assessment

Broad incumbents

  • AiCuris Anti-Infective Cures: AiCuris is a specialty anti-infective company with a broader anti-infective pipeline. As Lysando's announced collaboration partner for diabetic foot infections, it operates in the same anti-infective space but with a wider portfolio beyond microbiome-targeted approaches.
  • Iterum Therapeutics: Iterum Therapeutics develops antibiotics targeting multi-drug resistant infections. While it operates in the same anti-infective space with conventional small-molecule antibiotics, it represents the established incumbent approach that Artilysins aim to displace.

Direct peers

  • Locus Biosciences: Locus Biosciences develops engineered bacteriophage-based antimicrobials targeting antibiotic-resistant bacteria. Its precision antimicrobial approach for treating resistant infections makes it a direct peer to Lysando's Artilysin technology.
  • Phagelux: Phagelux develops phage-based products for bacterial infection control across human health, animal health, and food safety. Its multi-species antimicrobial platform and animal health focus directly parallel Lysando's positioning with Amicogen.
  • ContraFect: ContraFect develops lysin-based therapeutics targeting serious bacterial infections, including drug-resistant pathogens. Its lysin modality is mechanistically similar to Artilysins, making it a direct peer in the novel antimicrobial protein space.
  • Kane Biotech: Kane Biotech develops biofilm-disrupting antimicrobial wound care products. Its focus on biofilm management in wound applications directly overlaps with Lysando's wound care use case, even though the underlying modality differs.
  • Eligo Bioscience: Eligo Bioscience develops precision antimicrobials using engineered phage-derived payloads to selectively eliminate specific bacteria. Its microbiome-preserving approach for targeted bacterial elimination directly parallels Lysando's Artilysin strategy.
  • Micreos: Micreos develops endolysin-based antimicrobial products (e.g., Staphefekt) that selectively target pathogenic bacteria while preserving beneficial microbiome. Its technology is the closest analog to Lysando's Artilysin platform, making it a direct peer in the precision antimicrobial space.

Emerging players

  • MatriSys Bioscience: MatriSys Bioscience develops live biotherapeutic products targeting skin microbiome for dermatological conditions. Its microbiome-focused approach to skin diseases provides a partial overlap with Lysando's dermatology indications.
  • Siolta Therapeutics: Siolta Therapeutics develops microbiome-based therapeutics for inflammatory diseases including atopic dermatitis. Its focus on microbiome modulation for skin conditions overlaps with Lysando's dermatology use cases (acne, eczema).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Lysando social profiles

Digital presence

Lysando financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lysando leadership team

Management profile

Number of profiles

Profiles1 record

Lysando funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lysando M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lysando

What does Lysando do?

Lysando develops and commercializes Artilysin® technology, a class of precision-designed antimicrobial protein molecules that selectively eliminate harmful bacteria while preserving beneficial microbiome communities. The company applies AI-driven protein design, supported by a proprietary database of more than 4,500 constructs, to develop therapeutic products for wound care, dermatology (acne, eczema), and animal health applications such as mastitis in dairy cattle. Revenue derives from product sales of Artilysin-based therapeutics and licensing of the underlying technology to pharmaceutical and healthcare partners.

Is Lysando a public or private company?

Lysando is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Lysando founded?

Lysando was founded in -1. It employs 11 to 50 people.

Where is Lysando based?

Lysando is headquartered in Triesenberg, Liechtenstein, in the Europe region.

How does Lysando make money?

One revenue line is on record: product Sales / Licensing.

Who are Lysando's main competitors?

Broad incumbents on record are AiCuris Anti-Infective Cures and Iterum Therapeutics. Direct peers are Locus Biosciences, Phagelux, ContraFect, Kane Biotech, Eligo Bioscience and Micreos. Emerging players are MatriSys Bioscience and Siolta Therapeutics.

Does Lysando have an API?

No public API is recorded for Lysando.

What industry is Lysando in?

Lysando's product category is Antimicrobial Therapeutics. Its primary akta.pro industry code is HLAMAEAE, Antimicrobials & Anti-infectives, with a secondary code of HLAHALAC, Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals